Identification of new markers for adjuvant therapy of pancreatic cancer
10.3781/j.issn.1000-7431.2024.2409-0582
- VernacularTitle:胰腺癌辅助治疗新标志物的鉴定
- Author:
Baiyong SHEN
1
Author Information
1. 上海交通大学医学院附属瑞金医院胰腺疾病诊疗中心,上海 200025
- Publication Type:Journal Article
- Keywords:
Pancreatic cancer;
Proteomics;
Prognostic models;
NDUFB8;
CEMIP2
- From:
Tumor
2024;44(12):1151-1155
- CountryChina
- Language:Chinese
-
Abstract:
In January 2024,professor Shen Baiyong's team at the Pancreas Center-Shanghai Key Laboratory of Translational Research in Pancreatic Tumor,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,published a research paper in Nature Medicine titled"Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma".The team conducted a prospective observational study that included a total of 1 171 pancreatic cancer patients who underwent radical resection.First,paired samples of tumors from 191 pancreatic ductal adenocarcinoma(PDAC)patients were obtained by microdissection and subjected to proteomic analysis,which revealed unique protein modules of pancreatic tumors,particularly those related to chemotherapeutic drug sensitivity.Further,the research team established a prognostic risk model for pancreatic cancer at the proteomic level and validated the validity and reliability of this prognostic model with an external cohort.Using multicenter and large sample data,the study constructed and validated the generalizability of two protein markers in predicting the efficacy of chemotherapy in pancreatic tumors.
